Haematological Cancer

(asked on 2nd May 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of funding for providing new treatments for blood cancer.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 14th May 2018

In England there is a well-established framework for enabling access to cost effective new cancer medicines. All new licensed cancer medicines are referred to the National Institute for Health and Care Excellence (NICE) for inclusion within the Technology Appraisal Programme. This referral is irrespective of the clinical indication concerned. Where cancer medicines are approved by NICE for use in England, NHS England makes these available immediately. NICE now also has the ability to refer licensed medicines demonstrating promising, but not yet certain, benefits for inclusion within the Cancer Drugs Fund.

Reticulating Splines